Oral pharmaceutical composition containing a polyethylene glycol

Details Oral pharmaceutical composition containing a polyethylene glycol Oral pharmaceutical composition containing a polyethylene glycol

1991-10-28

1992-12-08

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Lymphokine

424 858, 5303911, 530406, 530410, A61K 39395, A61K 3944

Patent

active

051696274

ABSTRACT:
Polyethylene glycol serum immunoglobulin conjugates exhibit substantial rstance to degradation by intestinal enzyme while retaining their immuno-activity. Thus, PEG-IgG or PEG-IgA conjugates can be used as orally administered therapeutics to treat patients with gastrointestinal immunodeficiency to reconstitute secretory immunity. Preferred conjugates are made by reacting activated PEG and IgG in ratios of from 1:5 to 1:1000 such that less than about 27% of the IgG lysine residues are bonded to the PEG. The conjugates are advantageously formulated into a pharmaceutical composition comprising the conjugate and a pharmaceutically acceptable oral carrier. Particularly for administration to infants, a preferred oral carrier is milk.

REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4477432 (1984-10-01), Hardie
patent: 4496689 (1985-01-01), Mitra
patent: 4714612 (1987-12-01), Nakamura et al.
patent: 4732863 (1988-03-01), Tomasi et al.

Affiliated with

Also associated with

Rating

Oral pharmaceutical composition containing a polyethylene glycol does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral pharmaceutical composition containing a polyethylene glycol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral pharmaceutical composition containing a polyethylene glycol will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-959564